Biogen Inc. has successfully completed its acquisition of Apellis Pharmaceuticals for $5.3 billion, enabling Apellis to function as a subsidiary. This strategic move comes as Apellis reported a 10.6% year-over-year revenue decline despite posting a Q4 2025 revenue of $200 million, exceeding expectations. Apellis's stock is currently fluctuating, with a recent monthly gain of 6.6%, as the merger aims to leverage combined strengths to enhance biopharmaceutical innovations.
“APLS · has traded between · $0.56 and $2.90 · over the last year”
“APLS · closed Tuesday's trade at · $0.77 · down 8.99%”
“Apellis Pharmaceuticals, Inc. (APLS) · reported · revenue · $178.49 million”
“Apellis Pharmaceuticals, Inc. (APLS) · experienced · year-over-year decline · 10.6%”
“Apellis Pharmaceuticals, Inc. (APLS) · had · EPS · -$0.33”
“Shares of Apellis Pharmaceuticals · returned · +6.6% · over the past month”
“APLS · has · market cap · $5.25B”
“APLS · has · volume · 68.61M”
“APLS · has · 52 week high · $41.14”
“APLS · has · 52 week low · $16.61”
“APLS · has · PE ratio · 41.01”
“APLS · has · price · $41.03”
